We use privacy-by-default, cookieless analytics.

Optional analytics cookies are used only if you accept them.

Read our Terms of Use and Privacy Policy.

WorkflowEU

EU MDR qualification workflow

Review this workflow before MDR classification. It turns intended purpose, claims, labels, instructions, software functions, accessories, Annex XVI products, IVD interfaces, medicinal interfaces, and borderline evidence into a recorded scope decision.

The output is a qualification rationale that can be handed to classification, notified-body selection, technical documentation, and conformity-route planning.

Back to main artifactReview sources
Author
Sorena AI
Published
May 9, 2026
Updated
Jul 24, 2026
Sections
4

Structured answer sets in this page tree.

Primary sources
4

Cited legal and guidance references.

Publication metadata
Sorena AI
Published May 9, 2026
Updated Jul 24, 2026
Overview

EU MDR qualification starts with the manufacturer's and the product evidence around it. Decide whether the product is a medical device, an , a covered without an intended medical purpose, an IVD-related product, a medicinal-product interface, or outside MDR scope before applying Annex VIII classification rules.

Section 1

Collect the qualification evidence first

Start by freezing the facts that define the . Under the MDR, intended purpose is read from manufacturer-supplied data on the label, instructions for use, promotional or sales materials or statements, and the clinical evaluation. A qualification file should therefore capture the live product claim set before anyone chooses a class or conformity route.

  • Collect the product description, variants, configurations, components, accessories, software modules, data sources, user groups, patient or consumer populations, markets, and economic-operator role.
  • Copy the wording from draft labels, instructions for use, package copy, app-store text, sales decks, website claims, support scripts, and clinical-evaluation assumptions.
  • List each function separately when software is involved: data collection, transformation, analysis, alarm generation, diagnosis or therapy support, monitoring, device control, device influence, communication, storage, or administrative workflow.
  • Record whether the product is supplied alone, in combination, as a system, as a procedure pack, as a component of another product, or as a replacement part intended to maintain or restore an existing device.
Sources for this answer
Regulation (EU) 2017/745 on medical devices
Defines intended purpose by reference to the manufacturer's label, instructions for use, promotional or sales materials or statements, and clinical evaluation.
Section 2

Decide whether the product is a device, accessory, or Annex XVI product

Apply MDR Article 2 before classification. A product qualifies as a medical device only when its intended use fits one of the listed medical purposes for human beings and its principal intended action is not achieved by pharmacological, immunological, or metabolic means, although those means may assist its function. Test status separately. For an without a medical purpose, Article 1(2) applies the MDR from the application date of the relevant common specifications rather than from the medical-device definition.

Annex XVI covers six product groups: non-corrective contact lenses and similar eye items; surgically invasive products used to modify anatomy or fix body parts without a medical purpose; dermal or mucous-membrane fillers other than tattoo products; equipment used to reduce, remove, or destroy adipose tissue; high-intensity electromagnetic-radiation equipment for skin treatment; and transcranial brain-stimulation equipment. Commission Implementing Regulation (EU) 2022/2346 supplies the common specifications and narrower inclusions or exclusions. For example, it excludes sunbeds and infrared equipment intended only to warm the body from its skin-treatment specifications. Record the exact product-group and common-specification match rather than treating every aesthetic product as an .

  • Device test: map the to diagnosis, prevention, monitoring, prediction, prognosis, treatment or alleviation of disease; injury or disability diagnosis, monitoring, treatment, alleviation or compensation; anatomy or physiological or pathological process investigation, replacement or modification; in vitro specimen-derived information; conception control or support; or cleaning, disinfection or sterilisation of covered devices.
  • Principal-action test: if the principal intended action is pharmacological, immunological, or metabolic, route the question to the medicinal-product interface instead of treating it as a simple MDR qualification.
  • test: decide whether the article is not itself a medical device but is intended to be used with one or more particular medical devices to enable their or directly assist their medical functionality.
  • Annex XVI test: identify the listed product group and the application date of its common specifications. Flag dual-purpose products because Article 1 requires them to meet cumulatively the requirements for the medical and non-medical intended purposes.
  • Borderline test: if the facts do not clearly resolve scope, keep a written rationale and identify whether the uncertainty concerns MDR, IVDR, medicinal products, cosmetics, food, biocides, human tissues or cells, or another product framework.
  • Authority route: MDR Article 4 allows the Commission, after consulting the MDCG, to determine by implementing act whether a specific product or product category meets the medical-device or definition. Until an applicable determination resolves the point, preserve the case-specific evidence and use the relevant competent-authority or legal route rather than treating an internal rationale as an official status decision.
Sources for this answer
Regulation (EU) 2017/745 on medical devices
Provides the medical-device definition, accessory definition, Annex XVI scope rule, dual-purpose rule, exclusions, and Commission borderline-determination mechanism.
Commission Implementing Regulation (EU) 2022/2346 on Annex XVI common specifications
Defines the common specifications and product boundaries used for the six Annex XVI groups, including the skin-treatment equipment exclusions.
Section 3

Separate IVD, medicinal, and product-safety interfaces only where the facts require it

Do not turn every qualification review into a survey of unrelated regimes. Use interface checks only where the collected evidence shows a real boundary question: specimen-derived information, medicinal substance action, a drug-delivery combination, or product-safety law overlap.

  • IVD interface: if the product or software provides information from in vitro examination of specimens derived from the human body, decide whether the IVDR governs the IVD part or the product as an IVD-related product before continuing under MDR.
  • MDR device with IVD part: when a device incorporates an IVD as an integral part, keep the MDR qualification for the device and record that IVDR requirements apply to the IVD part.
  • Medicinal-product interface: when a product combines a medicinal product or substance and a device, record the principal mode of action. If a substance that would be a medicinal product acts only ancillary to the device, document the MDR route and the medicinal-substance consultation trigger for later conformity planning.
  • Drug-administration interface: if the article administers a medicinal product, record whether it is a device governed by the MDR or a single integral product governed by the medicinal-product framework. For the latter route, the device part must meet the applicable Annex I GSPRs and, where Article 117 applies, the marketing-authorisation dossier must include the available conformity-assessment results or, when those results are absent and separate-device assessment would require a notified body, a notified-body opinion.
  • Product-safety interface: for non-device products, replacement parts, or general-purpose software, document why MDR does not apply and hand the item to the relevant product-safety, machinery, software, cosmetic, food, biocidal, or contractual review only when the source support facts support that handoff.
Sources for this answer
Regulation (EU) 2017/745 on medical devices
Grounds MDR exclusions and interfaces for IVDR products, medicinal products, integral IVD parts, medicinal substances with ancillary action, and medicinal-product administration devices.
Regulation (EU) 2017/746 on in vitro diagnostic medical devices
Source for the IVDR interface where software or a product is driven by in vitro diagnostic information rather than MDR device information.
Section 4

Record the rationale and hand off to classification and conformity planning

The qualification output should be a short, inspectable rationale rather than a meeting note. It should show the collected claims, the Article 2 or Article 1 path taken, the exclusions considered, the sources used, the unresolved assumptions, and the exact point where classification begins.

  • State the result as one of these outcomes: MDR medical device, MDR , MDR , MDR device with IVD part, medicinal-product route with device-part requirements, IVDR route, outside MDR scope, or unresolved borderline issue.
  • For MDR outcomes, hand the file to Annex VIII classification with , duration, invasiveness, active-device status, software independence or device influence, medicinal-substance presence, tissues or cells, sterile status, measuring function, and Annex XVI status already identified.
  • For software, decide whether it drives or influences another device, is independent and classified in its own right, or is general-purpose or administrative software outside the device definition.
  • For non-Class I or otherwise notified-body-involved routes, carry forward the qualification rationale into notified-body scope checks, technical-documentation planning, clinical-evidence planning, UDI planning, and declaration-of-conformity planning.
  • Escalate to regulatory counsel or competent-authority strategy when the rationale depends on a borderline interpretation, principal mode of action, or another EU framework that the qualification file cannot resolve from the available evidence.
Sources for this answer
Regulation (EU) 2017/745 on medical devices
Grounds the handoff from qualification to Annex VIII classification, including intended-purpose-based rules, separate classification of accessories, and software classification rules.
European Commission - notified bodies for medical devices
Commission source for the notified-body context used when a qualified and classified MDR product needs conformity-assessment route planning.
Recommended next step

Turn qualification into a defensible MDR scope record

Use the qualification rationale to align product claims, software functions, labels, instructions, regulatory interfaces, classification inputs, and conformity-route planning before launch or major product change.

Research workflow
Open Research Copilot

Resolve MDR scope, interface, and classification questions with cited outputs.

Explore next step
Talk to Sorena
Talk through MDR qualification

Review intended purpose, claims, software functions, borderline issues, and conformity-route inputs.

Explore next step
Primary sources

References and citations

Regulation (EU) 2017/745 on medical devices
eur-lex.europa.eu
Referenced sections
  • Grounds the handoff from qualification to Annex VIII classification, including intended-purpose-based rules, separate classification of accessories, and software classification rules.
"classification rules"
Related guides

Explore more topics

Custom-made medical devices under the EU MDR | EU MDR FAQ
Concise EU MDR FAQ on custom-made device definition, mass-produced exclusions, Annex XIII statements, documentation, conformity assessment, PMS, vigilance, and records to retain.
EU MDR Annex II and III Technical Documentation
Build an MDR technical documentation index for Annex II device files and Annex III post-market surveillance evidence, including GSPR, risk, clinical, PMS, UDI, and EUDAMED records.
EU MDR Annex VIII Classification Guide
Classify EU MDR medical devices under Annex VIII using intended purpose, duration, invasiveness, active device and software rules, and conformity assessment impact.
EU MDR Annex XVI products without a medical purpose
EU MDR guide for Annex XVI products: listed groups, common specifications, binding reclassification rules, clinical evidence, notified-body route, transition conditions, UDI, EUDAMED, PMS, and vigilance.
EU MDR Applicability Test
Test whether a product, accessory, software function, or Annex XVI product falls under the EU Medical Device Regulation, and record the evidence for the next classification step.
EU MDR change assessment workflow
Assess EU MDR device, design, software, intended purpose, QMS, clinical, PMS, UDI, classification, and notified-body impacts before releasing a medical device change.
EU MDR Checklist for Medical Device Compliance
Practical EU MDR checklist covering qualification, classification, conformity assessment, technical documentation, GSPR, clinical evidence, UDI, EUDAMED, PMS, vigilance, QMS, and legacy transition evidence.
EU MDR classification workflow
A concrete EU MDR classification workflow for intended purpose, device or accessory qualification, Annex VIII rule selection, Rule 11 software review, class outcome, and notified body impact.
EU MDR Clinical Evaluation Overview
EU MDR clinical evaluation overview covering Article 61, Annex XIV, clinical data sources, equivalence, PMCF, CER evidence, notified body review, GSPR, and benefit-risk support.
EU MDR Clinical Evaluation Report Template
A cited EU MDR clinical evaluation report template covering intended purpose, GSPR linkage, clinical data appraisal, equivalence limits, PMCF, conclusions, and reviewer signoff.
EU MDR clinical evidence guide
EU MDR guide to clinical evaluation, clinical investigations, equivalence, PMCF, GSPR support, technical documentation, and notified-body review.
EU MDR compliance obligations
EU MDR compliance guide for device qualification, classification, conformity assessment, QMS, technical documentation, UDI, EUDAMED, PMS, vigilance, and legacy transition controls.
EU MDR conformity route workflow
EU MDR workflow for classifying a device, choosing the conformity assessment route, preparing technical and QMS evidence, and reaching certificate, DoC, UDI, EUDAMED, and CE outputs.
EU MDR deadlines and compliance calendar
EU MDR calendar for application, conditional legacy-device transition, UDI carrier dates, mandatory EUDAMED modules, and recurring compliance reviews.
EU MDR Device Classification Guide
Classify an EU MDR medical device by intended purpose, Annex VIII duration, invasiveness, active-device and software rules, then document the conformity route impact.
EU MDR EUDAMED and UDI registration
cited MDR guide to Basic UDI-DI, UDI-DI, EUDAMED device registration, actor roles, labels, technical documentation, and UDI data governance.
EU MDR FAQ: qualification, evidence, UDI, and transition
Concise EU MDR FAQ covering device qualification, software classification, accessories, custom-made devices, clinical evidence, UDI, EUDAMED, notified bodies, significant changes, and legacy transition.
EU MDR Legacy Device Transition
EU MDR legacy-device guide to Article 120 eligibility, class-based end dates, certificate validity, significant changes, surveillance, and evidence.
EU MDR notified body route selection
Choose an EU MDR conformity assessment route by device class, Article 52 option, notified body designation scope, QMS readiness, technical documentation, clinical evidence, and certificate evidence.
EU MDR penalties and enforcement risk
EU MDR guide to Article 113 national penalties, authority measures, recalls, certificate action, and the evidence needed for a country-specific assessment.
EU MDR PMS and Vigilance Guide
EU MDR guide to post-market surveillance, PMCF updates, PMS reports, PSURs, serious incident reporting, FSCA/FSN handling, trend reporting, and evidence records.
EU MDR PMS and vigilance records
Cited EU MDR guide to PMS plans, PMS reports, PSURs, PMCF updates, serious incident and FSCA reporting, trend reporting, and EUDAMED evidence handling.
EU MDR PMS Plan Template for Medical Devices
A cited EU MDR post-market surveillance plan template covering device scope, PMS data sources, PMCF linkage, vigilance, trend reporting, PMSR or PSUR outputs, roles, cadence, and evidence records.
EU MDR QMS and technical file evidence map
Map EU MDR Article 10 QMS duties to Annex II and Annex III technical documentation, PMS, vigilance, UDI records, and notified-body review evidence.
EU MDR QMS requirements under Article 10
EU MDR QMS guide for Article 10 manufacturer controls covering regulatory strategy, design, risk, clinical evaluation, PMS, vigilance, UDI, suppliers, CAPA, and conformity records.
EU MDR qualification and borderline products
EU MDR qualification guide for medical purpose claims, accessories, software, Annex XVI products, and borderline routes to classification and conformity assessment.
EU MDR requirements checklist
Concrete EU MDR requirements for medical-device scope, classification, GSPR, conformity assessment, technical documentation, QMS, clinical evidence, UDI, EUDAMED, PMS, vigilance, and economic-operator records.
EU MDR Rule 11 software classification
Classify MDR medical device software under Rule 11 using intended purpose, diagnosis or therapy decision impact, physiological monitoring, conformity route, clinical evidence, and software-change records.
EU MDR significant changes FAQ: legacy-device transition and notified-body review
FAQ on MDR significant changes for legacy devices, including intended-purpose, design, software, material, sterilisation, clinical, QMS, notified-body, and evidence impacts.
EU MDR SSCP: Devices and Requirements
Decide whether an EU medical device needs an SSCP, see worked class IIa, IIb, and III examples, and check the required content, evidence, publication, and update controls.
EU MDR transition timeline and end dates
EU MDR chronology for 2021 application, 2023 amendments, 2024 eligibility milestones, and conditional 2026, 2027, and 2028 transition endpoints.
EU MDR UDI and EUDAMED registration guide
EU MDR guide to Basic UDI-DI, UDI-DI, UDI carriers, EUDAMED actor and device registration, change impacts, and evidence governance.
EU MDR vigilance reporting workflow
Concrete EU MDR vigilance workflow for incident intake, serious incident assessment, FSCA and FSN handling, trend reporting, EUDAMED caveats, CAPA, PMS, clinical evaluation updates, and records.
How should Basic UDI-DI and UDI-DI be assigned under the EU MDR? | EU MDR FAQ
EU MDR FAQ on Basic UDI-DI grouping, device and package UDI-DIs, UDI carriers, EUDAMED registration, change triggers, and required records.
MDR vs AI Act for medical-device software
Compare MDR and AI Act scope, high-risk classification, conformity assessment, evidence, monitoring, and timing for AI-enabled medical devices.
MDR vs EU Product Liability Directive
Compare MDR compliance evidence with EU product-liability claims, responsible parties, disclosure, presumptions, damage, and the December 2026 transition.
MDR vs GPSR: medical-device boundary checks
Compare MDR medical-device scope with general product-safety fallback questions for borderline, non-medical, and Annex XVI products.
MDR vs IVDR: medical devices and IVDs compared
Compare EU MDR and IVDR scope, classification, conformity routes, technical documentation, clinical or performance evidence, UDI, EUDAMED, PMS, and vigilance.
What should an EU MDR PMCF plan and report cover? | EU MDR FAQ
Under the EU MDR, PMCF is part of PMS and clinical evaluation. See what the plan, activities, report, updates, and retained evidence should cover.
What should manufacturers do when an EU MDR classification changes? | EU MDR FAQ
Concise EU MDR FAQ on classification changes, intended purpose, software, notified-body route impact, certificates, technical documentation, and retained evidence.
When can clinical equivalence be used under the EU MDR?
EU MDR FAQ on clinical equivalence, including technical, biological, and clinical characteristics, access to equivalent-device data, class III and implantable-device limits, clinical evaluation, PMCF, and retained evidence.
When do software or products make medical purpose claims under the EU MDR? | EU MDR FAQ
EU MDR FAQ on medical purpose claims, intended purpose evidence, software qualification, Annex XVI contrasts, and records to keep.
When is a PSUR required under the EU MDR and what should it contain? | EU MDR FAQ
EU MDR FAQ on PSUR scope, content, update cadence, PMS and PMCF links, notified-body handling, EUDAMED submission, and evidence to retain.
When is an accessory regulated under the EU MDR? | EU MDR FAQ
EU MDR FAQ on when an article is a medical device accessory, how intended purpose affects classification, and what evidence to keep.
When is software a medical device under the EU MDR?
EU MDR FAQ on medical device software qualification, Rule 11 and other classification rules, modules, evidence, software changes, UDI, and EUDAMED.
Which EUDAMED modules matter under the EU MDR? | EU MDR FAQ
EU MDR FAQ mapping EUDAMED modules to actor registration, UDI/device data, certificates, clinical investigations, vigilance/PMS, market surveillance, and practical records.